{"name":"Protalix","slug":"protalix","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AIR DNase","genericName":"AIR DNase","slug":"air-dnase","indication":"Cystic fibrosis","status":"phase_2"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"PRX-102 (pegunigalsidase alfa)","genericName":"PRX-102 (pegunigalsidase alfa)","slug":"prx-102-pegunigalsidase-alfa","indication":"Fabry disease (in development)","status":"phase_3"}]}],"pipeline":[{"name":"AIR DNase","genericName":"AIR DNase","slug":"air-dnase","phase":"phase_2","mechanism":"AIR DNase is a recombinant human deoxyribonuclease that degrades extracellular DNA to reduce mucus viscosity and improve airway clearance in cystic fibrosis.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"PRX-102 (pegunigalsidase alfa)","genericName":"PRX-102 (pegunigalsidase alfa)","slug":"prx-102-pegunigalsidase-alfa","phase":"phase_3","mechanism":"PRX-102 is a pegylated recombinant human α-galactosidase A enzyme that breaks down accumulated globotriaosylceramide (Gb3) in cells affected by Fabry disease.","indications":["Fabry disease (in development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNQWY5Sl90TkpUeWRIZUJKd285cjYybU5IX0hoWEZISVRmbnFlTk5PYnZiNkFhbVlPOW05TVdhQ1pWOXRHMTVHRjV6MUtnOEZQcXRHNXlFaVlQTlhJUm9UeTRFY0lEZkJEMmxWR3NLTjB2U2swRUVZUHczSVg2X0ZEQjdjQ1dXOEtIdXllemVNV2ZtSUJoWFV0bFRvUU5pYlZabnFVM3VGdVJPR3I4RzZ1bktJYWlvWHJiTEJodlFaTks3cWZlV084dWJtYUdwOXBqWE1UYmQ5bjJPVms?oc=5","date":"2026-01-30","type":"pipeline","source":"proactiveinvestors.com","summary":"Protalix wins EU panel backing for expanded dosing of Fabry disease drug - proactiveinvestors.com","headline":"Protalix wins EU panel backing for expanded dosing of Fabry disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQd210SkpnTzIyaS1Zd1ZZSGVRb2sta0k3V0FZUDlaT1BrSWhVMzhYZ2p2NmNBc1VtemJwUWljTjBnV3dieHpUT1NBMWdyT1c5dDFReGtWcjhzenVyeU5BNHhDY2hMQUZYdG1Za3lQaEVSXzdaZjNlaWhHUWptTHJsTkQzdnJuT0JqUVE?oc=5","date":"2025-10-17","type":"pipeline","source":"Yahoo Finance","summary":"Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance","headline":"Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Reg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxORkxNUFhteGgxNHpPUW9BbWpYejh6ZFhZWnB6eHdhQ01xVmVobnhjR3hzZDRYV2p6Y3dwdDZIbUhkN3lkSERyZ3V6UjlrVEZtYlo1MHBIUERtSUdWRzdxenVjbkdYOEZnU0w4QlFQX3lWM1RMRHdTdUZsQVliWndVREdESkNEcThBQWF4N3R5b2Qzdw?oc=5","date":"2025-07-21","type":"pipeline","source":"Contract Pharma","summary":"Protalix BioTherapeutics Names SVP and CFO - Contract Pharma","headline":"Protalix BioTherapeutics Names SVP and CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNZ2Nidjk1Nk5oS3Nqd2FFbGhCMXVLaDFsTHIzWF9JMVVMM1pOVGJiTkMzVHNQTTk3c1U4RXpGRUZVQ2hqQy1jRWVXRVpxaHBHZTh4RzVNbzg1VVZxN2FOaXVkbmNnUVpHOEVvQ1JWQ0ZRbTFtVDdFa1hmeDloZVlGZmZ1NDc?oc=5","date":"2024-12-10","type":"regulatory","source":"Pharmaceutical Technology","summary":"EMA validates Chiesi/Protalix’s submission of pegunigalsidase alfa - Pharmaceutical Technology","headline":"EMA validates Chiesi/Protalix’s submission of pegunigalsidase alfa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQUy1McGJ3NF9vMFBuMFVpMkxfb3ZSOHRodGh0SjE2WU5OQW5QeVdPN0c4VXo1Tlc4N0ZsdFlLVmRCOWF6VlJOOFE2bUJhem4wb0czVUdlME9ITzRzRUFpYjFuZWJNSURJTHNwODVTRHdTUHZMNWhTOHNBT0xRX1o5Y3lDNUFhYW9mWHJXMmRDamoyQnM?oc=5","date":"2024-08-01","type":"pipeline","source":"pharmacytimes.com","summary":"Clinical Overview: Elfabrio for Fabry Disease in Adults - pharmacytimes.com","headline":"Clinical Overview: Elfabrio for Fabry Disease in Adults","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNMVBaRmxTUlZYYlVWSDVjcTktZFljZjFfcE9VbDlMR29mYUNmdGhENU1KMTRoVG1NcnVtUVphMnJuMXB0V0tCb1ZGVFZIOVFPMDBjQ3NNTC1ETWdnOFJGTy12Y2VJM1VLbDZzYlQ0bmlGRlhBb0Y0dlpPZ2hwb213TW01Z1RETzBBTU9vbFdtcjhaZHdMZERpbWlRQ0dCa2c1SVB2MXVkWjJrSXk5V0Z4Z1VneTlreEFEX0h2dW54NGpnRGt0a29fLW5xZEZoMDg4V0dDRGhvMDV1Q3hmQTlNcmJieVBmTEdoRXlvZ0hvcXdqbDdFazdMSGEwSU4yQkFGdVg4R1Nla3lXQ19hOUtwX0lJZVlBLTFVQkpF?oc=5","date":"2024-07-15","type":"regulatory","source":"PR Newswire","summary":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight - PR Newswire","headline":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Disea","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQNWhqOXk4T25pSWZ3N0FJcWtUbGF0aE1XNVpwa2pybkJBVG4xcUdvaV92SnRJY2lXdndHNFBwTUtGeXQ4Sl9qY1pJd2tOcXM4ZzZRYkdYbEhfZmZEMUh6ZWpfR24wakptYzZfTXJ2TU5rNTZnWlFoTFdzM2RRLTRwRDJnYlNqSGdTUEE?oc=5","date":"2023-05-10","type":"regulatory","source":"BioSpace","summary":"FDA Approves Fabry Disease Treatment from Chiesi, Protalix - BioSpace","headline":"FDA Approves Fabry Disease Treatment from Chiesi, Protalix","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZElyeVBKeXJ0ZGIzSGxBVHgtclVBTUhjcGQ5ajhXUkVxV0lId1VlajV0S2RXTzRucUZoMzJTX0VaR3ZpYlo3b2lBaWt3TXp1UnRMMDE4WXFJdVVEd0pxT2U4LWtoYUxiMlhGWW9XQ2VRUTNuRU9VMlhuVkcyRUlBSEJMZy1nQ0o3Rm5QWl91VzJJamtCT2Q0SjJtS2l6RGRmOUhneHgwcjdWRENaZ0pIT0lYMA?oc=5","date":"2023-05-05","type":"regulatory","source":"Fierce Pharma","summary":"Protalix, Chiesi challenge Sanofi with EU approval for Fabry disease med as FDA decision looms - Fierce Pharma","headline":"Protalix, Chiesi challenge Sanofi with EU approval for Fabry disease med as FDA decision looms","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQYTZZWlZjQU5JMVRnMFJTZm9TZzAtQU5zS2o1bl9fSE5aTll6RmlZQ2hsaXdlYi1MYXBQbHFUcXNWbm5JUWxESGgtUUtvRFg5WGd6ZDM3elB4SVM3YVltX0NhYzl6TldMajhiR3ppd1poZ0ZlWDdnOC03X1lZMlZEUGt1dE9lQTVES1RuLWE0cy16d0RxZld6azNLMnBHRFNzWFdqbmZyOXl1Ti12TThFbVRBNA?oc=5","date":"2020-03-12","type":"pipeline","source":"The Pharma Letter","summary":"$43.7 million financing for Protalix’ Fabry disease and other programs - The Pharma Letter","headline":"$43.7 million financing for Protalix’ Fabry disease and other programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOU1FvSVlESDVjYlQ5ZFdoTUdIcWlxQlQ1ZjVaLTZOTnIyNWRtVUJIM1dmZ1dPV1Izb1J0cGhQTGJBSE00Mk5ydVRKV21qLXk4bU94dXNqYzZVTElnUEZPanBlSzQ5Tmc0ZUlfTTJhZ2ZUSUV0ZldUOFV3VFJWZnhDM1VMVlAyOFJNQ3RBYmI1OGpLeHJPR2lra1BfQkJ1djREWXdQRjNR?oc=5","date":"2018-07-25","type":"deal","source":"BioPharma Dive","summary":"Chiesi adds US rights to Fabry disease drug in Protalix deal - BioPharma Dive","headline":"Chiesi adds US rights to Fabry disease drug in Protalix deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2014-07-01","type":"pipeline","source":"CNBC","summary":"This drug became kosher (but it doesn't matter) - CNBC","headline":"This drug became kosher (but it doesn't matter)","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}